Evidence map›Paper›PMID 39140053›Full record

ArticleACS medicinal chemistry letters2024

Predictions of Chromatography Methods by Chemical Structure Similarity to Accelerate High-Throughput Medicinal Chemistry.

Jun Wang, Rose Yen, Armen G Beck, Pankaj Aggarwal, May Kong, Michael Hayes, Salman Jabri, Thomas J Greshock, Kanaka Hettiarachchi

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jun WangDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.
Rose YenDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.
Armen G BeckAnalytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0009-0006-2193-0807
Pankaj AggarwalAnalytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, New Jersey 07065, United States.
May KongDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.
Michael HayesDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.
Salman JabriDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.
Thomas J GreshockDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.ORCID https://orcid.org/0000-0002-3313-9733
Kanaka HettiarachchiDiscovery Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States.ORCID https://orcid.org/0000-0001-8102-2997

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We introduce a new workflow that relies heavily on chemical quantitative structure-retention relationship (QSRR) models to accelerate method development for micro/mini-scale high-throughput purification (HTP). This provides faster access to new active pharmaceutical ingredients (APIs) through high-throughput experimentation (HTE). By comparing fingerprint structural similarity (e.g., Tanimoto index) with small training data sets containing a few hundred diverse small molecule antagonists of a lipid metabolizing enzyme, we can predict retention time (RT) of new compounds. Machine learning (ML) helps to identify optimal separation conditions for purification without performing the traditional crude QC step involving ultrahigh performance liquid chromatography (UHPLC) analyses of each compound. This green-chemistry approach with the use of predictive tools reduces cost and significantly shortens the design-make-test (DMT) cycle of new drugs by way of HTE.

Identifiers

PMID39140053
PMCPMC11318006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.